Domestic price of tucatinib

Tucatinib (tucatinib) is an investigational oral highly selective HER2 tyrosine kinase inhibitor. Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer have disease progression after receiving multiple HER2-targeted drugs, and their treatment options are limited. It is given to people who have had two or more treatments for HER2-positive breast cancer. HER2-positive breast cancer cells have too much of a protein called HER2 on their surface, which promotes cell growth.

Tyrosine kinase inhibitors(TKIs) which block the HER2 protein on cancer cells, thereby preventing the cells from dividing and growing Tucatinib is used to treat HER2-positive advanced breast cancer, often along with a chemotherapy drug called capecitabine and an anti-cancer drug called trastuzumab. Each course lasts 21 days (3 weeks), and tucatinib, trastuzumab, and capecitabine are usually continued until they work or the side effects become too severe.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug specifications150mg*60 tablets per box listed overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of Tucatinib produced in other countries. The price of 150mg*60 tablets per box produced by Laos pharmaceutical factory is around 6,400 RMB (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.